-+ 0.00%
-+ 0.00%
-+ 0.00%

Xenetic abstract on DNase I boosting CAR-T efficacy accepted for ASCO presentation

PUBT·04/22/2026 13:11:02
Listen to the news
Xenetic abstract on DNase I boosting CAR-T efficacy accepted for ASCO presentation
  • Xenetic Biosciences announced acceptance of a preclinical immuno-oncology abstract for presentation at 2026 ASCO Annual Meeting.
  • Data will be presented June 1, 2026, in a poster session in Chicago.
  • Research supports a DNase I approach targeting cfDNA and NETs to boost CAR T-cell function, aiming to improve antitumor activity.
  • Update signals continued development of Xenetic’s DNase-based platform, positioning it as a potential enhancer for CAR T therapies in hard-to-treat cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604220900ACCESSWRNAPR_____1159779) on April 22, 2026, and is solely responsible for the information contained therein.